Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) was the recipient of a large growth in short interest during the month of December. As of December 30th, there was short interest totalling 688,300 shares, a growth of 38.7% from the December 15th total of 496,400 shares. Based on an average daily volume of 95,600 shares, the days-to-cover ratio is presently 7.2 days. Currently, 3.9% of the company's shares are short sold.
Analyst Upgrades and Downgrades
Separately, JMP Securities increased their price target on shares of Aura Biosciences from $26.00 to $30.00 and gave the company a "market outperform" rating in a research report on Friday, November 11th.
Get
Aura Biosciences alerts:
Insiders Place Their Bets
In related news, CFO Julie B. Feder sold 2,015 shares of the business's stock in a transaction that occurred on Monday, October 31st. The shares were sold at an average price of $12.45, for a total transaction of $25,086.75. Following the completion of the sale, the chief financial officer now directly owns 24,235 shares of the company's stock, valued at $301,725.75. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director David Michael Johnson acquired 10,000 shares of the company's stock in a transaction that occurred on Thursday, December 1st. The stock was acquired at an average price of $12.37 per share, for a total transaction of $123,700.00. Following the completion of the acquisition, the director now owns 15,000 shares of the company's stock, valued at approximately $185,550. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Julie B. Feder sold 2,015 shares of the firm's stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $12.45, for a total value of $25,086.75. Following the transaction, the chief financial officer now owns 24,235 shares in the company, valued at approximately $301,725.75. The disclosure for this sale can be found here. In the last three months, insiders bought 1,264,396 shares of company stock valued at $15,166,660 and sold 4,802 shares valued at $59,796. Company insiders own 5.00% of the company's stock.
Institutional Investors Weigh In On Aura Biosciences
Large investors have recently modified their holdings of the business. Regency Capital Management Inc. DE bought a new position in shares of Aura Biosciences during the second quarter worth about $3,608,000. Millennium Management LLC bought a new position in shares of Aura Biosciences during the 2nd quarter worth approximately $325,000. Bank of New York Mellon Corp bought a new position in shares of Aura Biosciences during the 1st quarter worth approximately $319,000. Rhumbline Advisers acquired a new stake in shares of Aura Biosciences in the second quarter valued at approximately $294,000. Finally, Bank of America Corp DE lifted its position in shares of Aura Biosciences by 53.5% in the first quarter. Bank of America Corp DE now owns 11,857 shares of the company's stock worth $261,000 after purchasing an additional 4,131 shares in the last quarter. 55.63% of the stock is currently owned by institutional investors.
Aura Biosciences Trading Down 3.6 %
AURA traded down $0.38 during mid-day trading on Thursday, hitting $10.07. The stock had a trading volume of 1,355 shares, compared to its average volume of 106,229. The stock's fifty day simple moving average is $12.05 and its 200-day simple moving average is $13.63. Aura Biosciences has a 1-year low of $9.43 and a 1-year high of $24.83.
Aura Biosciences (NASDAQ:AURA – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.01). Equities research analysts anticipate that Aura Biosciences will post -2.02 EPS for the current year.
Aura Biosciences Company Profile
(Get Rating)
Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
Featured Stories
- Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
- 3 Attractive Defensive Stocks With 3% Dividends
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
